CMR (n=29) | Non-CMR (n=16) | P value | |
Age (years) | |||
Median (minimum, maximum) | 65.7 (39.9, 82.0) | 75.5 (58.3, 84.6) | 0.03 |
Gender | |||
female | 13 (45%) | 6 (38%) | |
male | 16 (55%) | 10 (62%) | 0.63 |
Histology | |||
Adeno | 23 (79%) | 11 (69%) | |
Squamous | 5 (17%) | 5 (31%) | |
Sarcomatoid | 1 (3%) | 0 (0%) | 0.65 |
PD-L1 expression | |||
0 | 5 (17%) | 0 (0%) | |
>0–<10 | 0 (0%) | 0 (0%) | |
≥10 | 17 (59%) | 11 (69%) | 0.27 |
Not reported | 7 (24%) | 5 (31%) | |
T status | |||
1 | 6 (21%) | 4 (25%) | |
2 | 5 (17%) | 3 (19%) | |
3 | 7 (24%) | 1 (6%) | |
4 | 11 (38%) | 8 (50%) | 0.57 |
N status | |||
0 | 7 (24%) | 0 (0%) | |
1 | 2 (7%) | 1 (6%) | |
2 | 9 (31%) | 6 (38%) | |
3 | 11 (38%) | 9 (56%) | 0.17 |
M status | |||
0 | 4 (14%) | 5 (31%) | |
1 | 25 (86%) | 11 (69%) | 0.24 |
UICC stage | |||
3 | 5 (17%) | 4 (25%) | |
4 | 24 (83%) | 12 (75%) | 0.70 |
Immunotherapy regimen | |||
Atezolizumab | 1 (3%) | 2 (12%) | |
Nivolumab | 16 (55%) | 5 (31%) | |
Pembrolizumab | 12 (41%) | 8 (50%) | |
Ipilimumab/nivolumab | 0 (0%) | 1 (6%) | 0.15 |
Treatment line | |||
First line | 12 (41%) | 13 (81%) | |
Non-first line | 17 (59%) | 3 (19%) | 0.01 |
Prior surgery | 9 (31%) | 2 (12%) | 0.28 |
Prior radiotherapy | 13 (45%) | 4 (25%) | 0.19 |
Prior chemotherapy | 21 (72%) | 7 (44%) | 0.06 |
Months immunotherapy until PET | |||
Median (minimum,maximum) | 30.8 (24.2, 53.0) | 30.0 (24.2, 50.5) | 0.90 |
Months until best objective response | |||
Median (minimum,maximum) | 7.8(1.1, 26.0) | 11.1(3.0, 30.1) | 0.12 |
Response according to RECIST | |||
PR | 24 (83%) | 12 (75%) | |
SD | 5 (17%) | 4 (25%) | 0.7 |
CMR, complete metabolic response; PET, positron emission tomography.